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The treatment of chronic myeloid leukemia (CML) has been radically changed by the
approval of tyrosine kinase inhibitors (TKIs), which target BCR-ABL1 kinase activity.
CML is now managed as a chronic disease requiring long-term treatment and close
molecular monitoring. It has been shown that in a substantial number of patients who
have achieved a stable deep molecular response (DMR), TKI treatment can be safely
discontinuedwithout loss of response. Therefore, treatment-free remission (TFR), through
the achievement of a DMR, is increasingly regarded as a feasible treatment goal in
many CML patients. However, only nilotinib has approval in this setting and a number of
controversial aspects remain regarding treatment choices and timings, predictive factors,
patient communication, and optimal strategies to achieve successful TFR. This narrative
review aims to provide a comprehensive overview on how to optimize the path to DMR
and TFR in patients with CML, and discusses recent data and future directions.
Keywords: chronic myeloid leukemia, deep molecular response, optimal strategies, treatment-free remission,
tyrosine kinase inhibitors
INTRODUCTION
The approval of tyrosine kinase inhibitors (TKIs), which target BCR-ABL1 kinase activity, has
significantly reduced the mortality rate associated with chronic myeloid leukemia (CML) and
revolutionized treatment (1). CML is now managed as a chronic disease requiring long-term
treatment. Currently, five TKIs are approved for the treatment of CML: imatinib, the first
TKI approved for this indication; second-generation TKIs, nilotinib, dasatinib, and bosutinib;
and ponatinib, a third-generation TKI (2–6). Imatinib, nilotinib, and dasatinib are currently
recommended for both first- and second-line treatments, bosutinib and ponatinib for second and
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later lines (7, 8). Compared with imatinib, newer TKIs are more
potent, act more rapidly, and are associated with higher response
rates (9–11).
The European LeukemiaNet (ELN) and European Society for
Medical Oncology (ESMO) guidelines recommend basing the
choice of first-line TKI on treatment goal, age and comorbidities,
considering the safety profile of the TKI (7, 8). Indeed, distinct
safety profiles for each of imatinib, nilotinib, and dasatinib have
emerged from clinical trials and clinical practice (9, 12–14).
Evidence from several studies suggests that in patients who
have achieved a sustained stable, deep molecular response
(DMR), TKI treatment can be safely discontinued with close
monitoring without relapse, despite BCR-ABL DNA remaining
detectable (15–22). As a consequence, DMR yielding treatment-
free remission (TFR) is increasingly regarded as a feasible
treatment goal in CML (23), however, TFR is only successful in
40–60% of patients (24).
With the growing availability of clinical trials and real-life
data on TFR in recent years, it has begun to seem increasingly
feasible to offer to CML patients a safe, informed, and shorter
path to TFR, through achieving a DMR. However, many
controversial aspects remain regarding treatment choices and
timings, predictive factors, patient communication, and optimal
strategies to achieve successful TFR.
The aim of this review is to provide an update on CML
management to achieve TFR, and to discuss recent data and
future directions.
WHO IS A CANDIDATE FOR
TREATMENT-FREE REMISSION TODAY
For the CML scientific community, TFR represents a striking
result of the last decade. However, two crucial questions remain
uppermost in the CML research agenda: (1) Can we further
extend the TFR opportunity to more patients? (2) How can we
accurately predict successful TFR or failure, in order to optimize
the patient-specific treatment strategy and duration?
Guidelines vs. the Real-Life
Treatment-Free Remission Population
The 2013 ELN recommendations state that CML patients
with optimal treatment response should continue treatment
indefinitely, with the possible consideration of TKI
discontinuation in individual patients only if a certified
high-quality monitoring at monthly intervals is available, or in
the context of well-designed, prospective, controlled studies (7).
While the newly published 2020 ELN recommendations (25)
mention TFR as a new significant goal in CML, they do not
provide a guide in treatment optimization to achieve TFR with
the current drugs available. Indeed, the Italian GIMEMA CML
Working Party (26) discuss and suggest treatment policies to
maximize TFR achievement, considered virtually a feasible goal
for all patients.
To date more than 30 clinical trials on TFR have been
conducted, and discontinuation of TKI therapy has been shown
to be feasible in patients with durable DMR (8, 27, 28), with
∼50% of patients reaching a successful discontinuation with
imatinib or second-generation TKIs (dasatinib and nilotinib).
In addition, criteria for stopping TKIs outside of clinical trials
(Table 1) have been suggested based on expert recommendations
(24, 30), and formal guidelines [ESMO (8) and the National
Comprehensive Cancer Network (NCCN) (29)].
According to the ESMO Clinical Practice Guidelines, the
availability of appropriate, high-quality and certified monitoring
is imperative when considering treatment discontinuation in
patients outside of clinical trials (8). Prerequisites for safe
stopping include: institutional requirements for safe supervision,
the identification of typical BCR-ABL1 transcripts at diagnosis,
at least 5 years of TKI therapy, achievement of MR4.5, and a
stable DMR (at least MR4) for at least 2 years (Table 1). Notably,
longer TKI therapy and longer DMR improve the stability of
TFR (31).
The NCCN guidelines (Version 1.2019) for CML state that,
outside of a clinical trial, discontinuation of TKI therapy appears
to be safe in selected CML patients (29, 32). Criteria for TKI
discontinuation include: age (≥18 years), chronic phase CML
(CP-CML; no prior history of accelerated or blast phase), prior
TKI therapy for ≥3 years, stable DMR (defined as at least MR4;
BCR-ABL1 ≤0.01% IS) for ≥2 years, and unceasing molecular
monitoring (Table 1). The new 2020 ELN recommendations,
recently published, also define minimal and optimal criteria for
discontinuation (Table 1). Thus, available recommendations are
discordant at some points, and, despite numerous clinical trials
demonstrating TFR feasibility in CML patients with DMR, the
optimal selection criteria for patients in clinical practice remain
uncertain (33), especially regarding the definition of DMR depth
and its duration, which seem to be the most important variables
associated with a successful TFR.
A number of studies have investigated clinical and biologic
predictive factors related to TFR success, aiming to delineate the
best criteria for discontinuation eligibility, however to date these
factors are far from impacting clinical choices, and a validated
TFR predictive model has not yet been developed.
In the imatinib suspension and validation (ISAV) study, both
age (<45 years) and a positive digital PCR status were shown to
predict relapse in CML patients who discontinued treatment with
imatinib (34). Indeed the highest risk of relapse was identified in
younger patients (<45 years) with digital PCR positivity (100%
at 15 months), suggesting that discontinuation of imatinib was
better achievable in the context of a continual negative digital
PCR status.
In IMMUNOSTIM, a translational study within the STIM
trial, significantly higher numbers of natural killer (NK) cells
were identified in non-relapsing compared with relapsing CP-
CML patients in DMR after imatinib discontinuation, suggesting
that NK cells may be associated with molecular relapse-free
survival (MRFS) after cessation of imatinib (35).
The EURO-SKI also identified the importance of NK cells
in maintaining remission after imatinib discontinuation in CML
patients, suggesting an association between an increase in MRFS
and a higher proportion of NK cells, which were mature and
secreted TNF-α/interferon (IFN)-γ cytokine in non-relapsing
patients (36).
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TABLE 1 | A summary of criteria for tyrosine kinase inhibitor discontinuation in clinical practice.
Criteria ELN 2020 (25)a NCCN 2018 (29)a ESMO 2017 (8)a Hughes et al. (24)b




History of CML CP only CP only CP only CP only
Sokal score at diagnosis Non-high Non-high




Response to first-line TKI Minimal criteria: No prior
treatment failure (except
intolerance of first-line TKI)
No resistance Optimal Optimal
Duration of TKI therapy Minimal criteria: > 5 yr (> 4 yr for
2GTKI)
Optimal criteria: >5 yr
≥ 3 yr ≥ 5 yr > 8 yr
Depth of DMR MR4 MR4 MR4.5 MR4.5
Duration of DMR Minimal criteria: ≥ MR4 for >2 yr
Optimal criteria: >3 yr if MR4 or
>2 yr if MR4.5
≥2 yr ≥MR4 for ≥2 yr >2 yr
Frequency of PCR
monitoring
Monthly for 6 mo, every 2 mo for
6 mo, every 3 mo thereafter
Monthly for 1 yr, every 6 wks for
1 yr, every 12 wks thereafter
Monthly for 6 mo, every 6 wks
for 6 mo, every 3 mo thereafter
Every 4–6 wks
PCR sensitivity At least MR4.5
PCR turnaround time Within 2 wks Within 4 wks
Resumption of TKI Within 4 wks of MMR loss
2GTKI, second-generation TKI; CML, chronic myeloid leukemia; CP, chronic phase; DMR, deep molecular response; ELN, European LeukemiaNet; ESMO, European Society for Medical
Oncology; MR, molecular response; MMR, major molecular response; mo, month; NCCN, National Comprehensive Cancer Network; PCR, polymerase chain reaction; RQ-PCR, real-time
quantitative reverse transcriptase-PCR; TKI, tyrosine kinase inhibitors; wks, weeks; yr, years.
*High-quality, internationally standardized, accurate, sensitive RQ-PCR laboratory; RQ-PCR test results within 4 weeks; Ability to run RQ-PCR testing every 4–6 weeks, if necessary;
Follow-up strategy in place to enable rapid treatment-resumption for loss of MMR.
aGuidelines.
bExpert opinion.
A significant positive correlation between the frequencies of
innate CD8(+) T-cells and NK cells was identified in CML
patients with TFR for ≥2 years after TKI discontinuation, which
is suggestive of a link between these lymphocyte populations
and may represent a novel innate biomarker of successful
TFR (37).
Younger age at discontinuation and line of treatment were the
only predictive factors that affected TFR in a univariate analysis
but these lost significance in the subsequent multivariate analysis
performed retrospectively in 293 CP-CML Italian patients in
DMR who discontinued TKI therapy (38). The DASFREE study
reported older age as a favorable prognostic factor of 2-years TFR
in patients with CML (age >65 years; p = 0.0012) (39). Given
these results, current recommendations do not consider age as a
limiting factor for discontinuation eligibility (26).
The potential predictive role of BCR-ABL transcripts (e13a2
and e14a2) in achieving a sustained DMR and TFR was assessed
in a number of studies, as recently reviewed (40). Indeed,
several large studies have shown transcript type to be associated
with outcome (41) or not associated with survival outcome
(42, 43). Even if an association with outcome is controversial, a
higher incidence of sustained DMR and TFR success was shown
for patients harboring the e14a2 transcript vs. e13a2, possibly
due to differences in immunogenicity, technical or genetic
reasons (41).
In patients with atypical BCR-ABL1 transcripts, TKI
discontinuation is not recommended in current guidelines
unless standardized methods for response monitoring are
available (see Table 1). However, TKI discontinuation was
recently reported in case series of seven patients carrying
atypical transcripts, with six out of seven patients remaining
off-treatment after a median follow-up of 25 months (range
5–77 months) (44). Further results are needed in this setting to
confirm these data.
As additional biologic criteria, the potential role of residual
leukemic stem cells (LSC) on TFR failure has been recently
investigated. Interestingly, the results have shown that flow
cytometry of peripheral blood could also detect residual
circulating CD26+ LSC in stable TFR patients, even if with
fluctuating values, with a progressive increase in relapsed patients
(45). Notably, this study showed no difference in CD26+
peripheral blood LSC between patients who relapsed or remained
in remission after TKI discontinuation.
Besides LSC, the lineage of residual BCR-ABL1-positive cells
is also under evaluation. A recent study from 20 CML patients in
TFR showed that leukemic lymphocytes appeared to be long lived
and may contribute to measurable residual disease (46).
Even if many factors are investigated, the “optimal” conditions
for TFR require further validation. Current recommendations
are in support of initial proposal at baseline of TFR strategy,
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informing on theminimum conditions for TFR eligibility, among
which, the achievement of a stable DMR is seen as the most
critical factor.
OPTIMIZING TREATMENT TO REACH A
DEEP MOLECULAR RESPONSE
The availability of multiple treatment options is a major advance
in CMLmanagement, but selecting the most appropriate TKI can
be challenging in routine clinical practice, and several practical
issues are still poorly defined by current guidelines.
First-Line Treatments: Clinical Trials and
Real-Life Data
The choice of first line therapy should take into account
tolerability, safety, age, and comorbidities, which may predict
specific toxicities with different TKIs (7), as shown by phase
III pivotal trials in large populations of newly diagnosed,
treatment-naïve CML patients (9, 10, 12, 47). The ENESTnd trial,
demonstrated a better long-term efficacy of nilotinib compared
with imatinib, that was recently confirmed in the 10-years follow-
up analysis (12, 48). By 5 years, significantly more patients treated
with nilotinib either 300 or 400mg twice daily achieved a major
molecular response (MMR) (77.0 and 77.2 vs. 60.4%, respectively,
p < 0.0001 for both comparisons vs. imatinib) and DMR (65.6
and 63.0 vs. 41.7% for MR4, and 53.5 and 52.3 vs. 31.4% for
MR4.5, respectively; p < 0.0001 for all comparisons vs. imatinib)
(12). At 10 years follow up, cumulative MMR rates were 82.6
and 80.4 vs. 69.6%, cumulative MR4 rates were 72.7 and 68.7
vs. 55.5%, and cumulative MR4.5 rates were 63.8 and 61.6 vs.
45.2%, respectively, and both nilotinib arms were associated with
a significantly lower probability of CML transformation from the
chronic phase to the accelerated and blast phases (48).
The 5-years results of the DASISION trial similarly showed
that dasatinib 100mg once daily was able to induce deeper
and faster molecular response compared with imatinib 400mg
once daily (MMR 76 vs. 64%, p = 0.0022; MR4.5 42 vs. 33%,
p = 0.0251) (9). Differently from the ENESTnd trial, the
number of progressions was not significantly inferior in patients
receiving dasatinib.
Published evidence also suggests that first-line treatment with
second-generation TKIs is successful in elderly CML patients
(49). A sub-analysis of the open-label ENEST1st trial, which
evaluated first-line nilotinib 300mg twice daily in over 1,000
CML patients, suggested that age did not influence response rates
and that DMR can also be achieved in elderly patients (49). After
18 months of treatment with nilotinib, the rate of MR4 in the
overall population was 38.4%; age-subgroup analyses revealed
similar MR4 rates in patients aged 18–39, 40–59, 60–74, and
≥75 years (33.9, 39.6, 40.5, and 35.4%, respectively). The MR4.5
rates at 18 months were also similar across age-subgroups (18.0,
22.4, 21.8, and 14.6%, respectively); the incidence of adverse
cardiovascular events, including arterial thrombotic events, was
significantly different in the age classes, suggesting caution in
elderly patients aged≥60 years.
In a real-life quantification of CP-CML patients treated
with first-line imatinib, dasatinib, or nilotinib (320, 24, and
53 patients, respectively, with a median follow-up of 9 years
for patients treated with imatinib, and 3 years for dasatinib-
and nilotinib-treated patients), 13, 29, and 45% of patients,
respectively, were eligible for TFR after a median TKI treatment
of 3 years (50). These data, which are in line with previous
clinical trials results, suggest that a sustained DMR may be
induced by second-generation TKIs over a shorter median
time compared with imatinib, and may enable an early TFR
eligibility. Thus, an appropriate selection of patients at baseline
can increase the proportion of potential candidates eligible for
TKI discontinuation.
Second-Line Treatments: Early and Late
Switch
Current recommendations do not provide a usable algorithm
aimed to delineate the best strategy of achieving DMR, either
through early or late switch, for patients whose response is not
early or not deep.
In a retrospective Chinese study, higher DMR rates have
been reported following early switching to nilotinib in CP-
CML patients with a warning molecular response at 3 months
compared with patients who continued imatinib treatment (51).
In this study, 46 patients had a warning response at 3 months
defined according to ELN-2013 recommendations, 26 patients
continued with imatinib, and 20 patients switched to nilotinib
300 or 400mg twice daily. With the limitation of the absence
of randomization, a higher percentage of patients receiving
nilotinib achieved a MR4 (61.5 vs. 18.6%; p = 0.035) by 4 years,
compared with imatinib-treated patients; however, a higher
proportion of high Sokal score patients was observed in patients
receiving imatinib and the number of treatment interruptions
was not reported.
Regarding late switch, the prospective ENEST-Complete
Molecular Remission (ENEST-cmr) trial reported that, in 207
CML patients with stable cytogenetic response but detectable
BCR-ABL1 levels on long-term imatinib, switching to nilotinib
was more effective for achieving DMR than continuing with
imatinib (52). Patients were randomized between switching to
nilotinib 400mg twice daily, or continuing imatinib 400mg once
daily. By 24 months, the rates of MR4.5 were 42.9 and 20.8%,
respectively among patients without MR4.5 at study start; among
patients without MMR at study start, or among patients in MMR
but without MR4.5 at study start, a MR4.5 by 2 years was achieved
by 29.2 vs. 3.6% and 47.3 vs. 27.9% of patients in the nilotinib and
imatinib arms, respectively. The final 48-months ENEST-cmr
results (53) confirm that continued imatinib therapy is associated
with lower DMR rates and also suggests that a late switch (after 2
years from enrollment) is less effective.
Treatment-Free Remission
The long-term durability and safety of TFR following frontline
nilotinib treatment were demonstrated in the 192-weeks results
of the ENESTfreedom study (54). ENESTfreedom was a single-
arm, phase 2 trial which assessed the potential for TFR
in patients with CP-CML who had ≥2 years of frontline
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nilotinib treatment and sustained DMR during a 52-weeks
nilotinib consolidation phase (defined as MR4.5 in the last
assessment, no assessment worse than MR4, and ≤2 assessments
between MR4 and MR4.5) (16). In total, 215 patients entered
the 52-weeks nilotinib consolidation phase and 190 patients
(88.4%) with sustained DMR throughout were eligible for
the TFR phase. In the TFR population, the median duration
of nilotinib prior to TFR was 43.5 months, and 98 patients
(51.6%; 95% CI, 44.2–58.9%) remained in remission after 1
year. At 192 weeks, the TFR rate was 44.2% (84 of 190
patients), MMR and MR4.5 were regained by 98.9% (90 of
91) and 92.3% (84 of 91) of patients, respectively, who
resumed nilotinib (54). There were no disease progressions or
CML-related deaths, and musculoskeletal pain-related events
were progressively reduced from the first to the 4th year
of discontinuation.
Likewise, the long-term durability and safety of TFR following
second-line nilotinib was demonstrated in the 192-weeks results
of the ENESTop study (55). In this study, patients were eligible
to attempt TFR after≥3 years of nilotinib treatment and without
confirmed loss of MR4.5 after a 1 year consolidation phase. Of
the 126 CP-CML patients with sustained DMR on second-line
nilotinib who entered the TFR phase, 56 patients completed
≥192 weeks of TFR, 59 patients resumed nilotinib, and 11
patients discontinued the study. The TFR rate at 192 weeks was
46.0% (58 of 126 patients), with 57 patients in MR4.5. MR4 and
MR4.5 were regained by 94.9% (56 of 59) and by 93.2% (55
of 59) of patients, respectively, who resumed nilotinib. Overall,
there were no deaths related to CML and no cases of disease
progression reported.
Based upon these two studies, nilotinib has received Health
Authority approval for attempting TFR.
In the 2-years update of the DASFREE study, including 84
patients with CP-CML and sustained DMR, TFR at 2 years
following dasatinib discontinuation was 46% (39). In this study,
patients were eligible to attempt TFR if they had received ≥2
years of dasatinib treatment and had dasatinib-induced MR4.5
for ≥1 year prior to study entry. Prognostic factors related to
maintaining TFR at 2 years were age, duration of prior dasatinib,
and prior therapy line.
A pre-specified interim analysis of EURO-SKI, which assessed
TKI discontinuation in a prospective, non-randomized trial of
755 CML patients who had received TKI for ≥3 years without
treatment failure (according to ELN recommendations) and with
confirmed DMR for at least 1 year, concluded that patients
who achieved long-term DMR have good MRFS and should be
considered for TKI discontinuation (31).
In a retrospective analysis of 293 Italian patients with CP-
CML in DMR who discontinued therapy with various TKIs (38),
patients discontinuing second-generation TKIs had a median
duration of treatment with the last TKI of 50 vs. 96 months of
treatment with imatinib. Furthermore, using multivariate Cox
regression model, a better probability of TFR for patients treated
with second-generation TKIs, with an estimated 57% relative risk
reduction vs. imatinib, was observed.
In a Spanish retrospective study of 236 CP-CML patients who
discontinued TKI treatment outside of clinical trials between
April 2009 and February 2018 (patients had received TKI for
≥3 years with sustained MR4.5 in ≥4 consecutive assessments
over a minimum of 2 years prior to discontinuation) (56),
treatment-free survival at 4 years was 64%; there were no cases
of disease progression and, in patients who failed to maintain
TFR, a DMR was regained 3–5 months after treatment was
restarted. A shorter duration of both TKI treatment (<5 years)
and time in MR4.5 prior to discontinuation (<4 years) were
shown by univariate analysis to significantly increase the risk of
molecular relapse.
To date, nilotinib is the only TKI with TFR included in
the Summary of Product Characteristics (3). According to the
updated dosing information, patients taking nilotinib for ≥3
years who are in sustained molecular remission (MR4.5, BCR-
ABL transcripts of ≤0.0032%) and can undergo appropriate
monitoring may be eligible to discontinue nilotinib. Implications
for clinical practice have recently been reviewed by Pulte and
colleagues (57).
Potential Issues of Treatment-Free
Remission
TKI withdrawal syndrome (TKI WS), which presents as
musculoskeletal pain, has been reported in patients shortly after
stopping TKIs (58). For example, in the ENESTfreedom study,
34% of patients reported musculoskeletal pain-related events
during the 1st year of the TFR phase, decreasing to 9, 3, and 3%
during the 2nd, 3rd, and 4th year (59). In a systematic review and
meta-analysis on the efficacy and safety of TKI discontinuation
(10 studies, n = 1,601), the weighted mean incidence of TKI
WS was 27%, with TKI WS appearing during the early TFR
phase (60).
Longer duration of TKI treatment and history of
osteoarticular symptoms were identified as risk factors that
predispose patients to TKI WS in an analysis of 427 CML
patients from the combined cohort of STIM2 and EURO-SKI
trials (61). TKI WS, which mainly involved the upper body
joints, occurred in 23% of all patients (i.e., 20.4, 41.4, or 40% of
patients developed TKI WS after stopping imatinib, nilotinib, or
dasatinib, respectively), and WS was confirmed to be a TKI class
effect. Therefore, one might speculate that musculoskeletal pain
is the result of rebound of symptoms previously suppressed by
TKIs. The optimal management of TKI WS is still poorly defined
but based mainly on non-steroidal anti-inflammatory drugs.
Cognitive dysfunction has also been reported following the
discontinuation of TKIs in patients with CML, highlighting the
necessity for vigilance regarding any unexplained neurological
occurrences (62).
The potential occurrence of sudden blast crisis should
also be mentioned: recently, a case was reported in the
STOP-2-Generation TKIs trial (63) and in a CP-CML patient
who attempted dasatinib discontinuation under clinical trial
conditions (NCT00254423) (64). These rare events required
further biological evaluation and as well as prospective
assessment in real-life, although this possibility seems to
be minimal based on data available from a number of
discontinuation trials to date.
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PATIENT MANAGEMENT STRATEGIES
AIMED TO IMPROVE THE WAY TO
TREATMENT-FREE REMISSION
The Role of Communication and
Adherence
Clinicians’ attitude toward treatment discontinuation has
changed over time. Nowadays, discontinuation of TKI treatment
is considered to be a safe procedure, whereas up until a few
years ago patients were more reluctant. Better knowledge of
patient motivations and concerns is imperative to facilitate TFR
as part of CML management (65). Results from a survey of 87
CML patients eligible for TFR showed that 81% were willing
to attempt TFR, with the most common motivations being
TKI toxicity (n = 26) and inconvenience (n = 18). However,
the fear of consequences of stopping TKI was the leading
reason for reluctance (n = 16), and was associated with an
incomplete understanding of current data and the need for
further information. This survey showed that most patients in
DMR would be willing to attempt TFR if recommended by their
treating physician and they were provided information on the
risk/benefits of TKI discontinuation as well as their likelihood
of maintaining TFR (65). In addition, a multicenter survey on
patient attitudes toward TFR in 329 CML patients identified
side effects (56%), high cost (52%), inconvenience (42%), and
pregnancy need (41%) as the main reasons for preferring
TFR; younger patients with shorter duration of disease and
higher burden of disease symptoms were more likely to attempt
TFR (66).
Perceptions about future discontinuation of TKIs were also
assessed in a patient-based survey of 1,133 CP-CML patients
(67). Overall, 42% of patients had postponed a dose on occasion
and therapy had been discontinued by 58% of patients, which
was mainly due to forgetfulness or side effects. Approximately
half of the patients surveyed were unwilling to discontinue
TKI treatment due to the fear of losing the beneficial results
they had achieved. Together, these results suggest the need for
communication improvement regarding the importance of DMR
achievement over time as predisposition to future potential TFR.
The European Steering Group offers a patient-centered
approach that educates patients about their treatment options,
including TFR, to facilitate patient-physician relationship and to
meet the needs of patients (emotional and psychological) within
the CML community (68). It clearly sets out recommendations,
based on a summary of the Steering Group discussion,
for physicians and CML patients considering TKI therapy
discontinuation. It outlines key topic areas for patient-physician
consideration regarding discontinuation and implications of
attempting TFR, as follows: CML treatment goals; what is
TFR and when is it appropriate; which patients might and
might not be eligible to attempt TFR; patient considerations
for discontinuing TKI; TKI WS; psychological implications;
molecular recurrence and retreatment.
Moreover, an Italian sub-study of ENESTPath examined the
psychological and emotional characteristics of CML patients who
failed TFR, defined as either ineligibility for TKI discontinuation
due to unstable molecular response (n = 8) or relapse during
TFR necessitating the reintroduction of nilotinib (n = 6) (69). A
slightly negative emotional experience was reflected in patients’
perception of TFR failure highlighting the emotional distress
experienced by CML patients. Patients were also reluctant to
believe that TFR success could lead to healing, which is not
unfounded since BCR-ABL DNA remains detectable even in
patients who have a successful TFR.
Poor adherence to therapy was shown to significantly reduce
molecular response rates in 87 patients with CML-CP treated
with imatinib (70). Several factors associated with high adherence
to TKI therapy have been reported including older age, male
sex, management of side effects, daily administration, and
patients feeling well-informed about CML by their doctor (71).
Importantly, a recent Polish study (72) reported there to be no
differences in treatment adherence in CML patients treated with
imatinib, dasatinib or nilotinib.
An optimal adherence may have an impact on TFR
probability, and should be recalled as a key factor among
strategies for maximizing the chance of achieving DMR. Risk
factors for a lower adherence should be identified and addressed
in order to increase the possibility of achieving stable DMR with
a shorter treatment. This is even more important considering
that previous reports indicate a higher risk of non-adherence
in younger patients, for whom treatment discontinuation is
even more important in the long-term to avoid possible specific
toxicities (71).
Molecular Monitoring
Prior to TKI discontinuation, a minimum of 3 years of approved
TKI therapy is recommended, with prior evidence of quantifiable
BCR-ABL1 transcripts and≥2 years of stable molecular response
(MR4; BCR-ABL1 0.01% IS) documented by ≥4 tests performed
≥3 months apart (29). Molecular monitoring post-treatment
suspension is also imperative for CML patients attempting TFR
(Table 1) but the minimum safe frequency is unknown. Recently,
a comparison of current NCCN recommendations (monthly
qPCR monitoring of BCR-ABL1 for 12 months following TKI
discontinuation) with less frequent monitoring (monthly testing
for 6months followed bymonitoring every 2months; monitoring
every 2 months for 6 months followed by monitoring every
3 months; monitoring every 3 months) was retrospectively
applied to data from 107 patients who attempted TFR (73).
Monitoring every 2 months for 6 months followed bymonitoring
every 3 months provided the optimal balance between reduced
monitoring and minimized the delay in detecting relapse and
recommencement of TKI. With reduced monitoring frequency,
a rapid turnaround time for PCR results is imperative as the
retrospective analysis also identified substantial increases in BCR-
ABL1 transcripts between detection of molecular relapse and TKI
recommencement (73).
A prerequisite for TKI discontinuation is standardized
molecular monitoring (8). The EUREKA registry evaluated the
assessment of DMR in CP-CML patients using standardized
molecular monitoring collected in the real-life practice context,
and compared results with EUTOS-certified laboratories
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(74). Results showed substantial agreement between EUTOS-
certified and local laboratories demonstrating reliable molecular
monitoring outside of clinical trials across six European
countries. In Italy since 2008, LabNet supports the diagnostics of
CML in 55 laboratories through standardization, collaboration,
and quality controls.
FUTURE DIRECTIONS IN TREATMENT
AND MONITORING TO IMPROVE TFR
OUTCOMES
New Drugs and Novel Strategies
Asciminib binds to the myristoyl pocket of ABL1 and is
a potent and specific inhibitor of BCR-ABL1. Data from
preclinical studies demonstrated cooperativity when asciminib
was combined with TKIs, suggesting that this combination
may provide more potent inhibition of BCR-ABL1 and
prevent the emergence of resistance mutations. Asciminib
demonstrated clinical activity and good safety and tolerability
as monotherapy in heavily pretreated CML patients with
resistance or intolerance to at least two prior TKIs in an
ongoing phase 1 study (NCT02081378) (75). Preliminary
results from the same trial have also demonstrated a good
safety profile and promising efficacy for the combination of
asciminib plus imatinib in 25 CP-CML patients (76), and
for asciminib plus nilotinib or dasatinib in 34 CML patients
in chronic or accelerated phase (77). Promising results of
asciminib monotherapy in heavily pretreated patients were
published recently (75). An ongoing phase 2 clinical trial
(clinicaltrials.gov identifier: NCT03578367) is investigating
asciminib plus imatinib in patients not achieving a DMR
with imatinib, with an estimated primary completion date of
March 2021.
The rationale for using IFN-α in order to maintain/improve
molecular response after TKI discontinuation was initially
demonstrated by Burchert et al. (78). Indeed, the combination
of IFN-α plus TKI has demonstrated good molecular responses
in CML patients, with significantly higher rates of molecular
response identified in patients treated with imatinib plus IFN-
α or with PEGylated IFN (Peg-IFN) alpha-2a compared with
imatinib alone (79, 80). Similarly, dasatinib plus Peg-IFN alpha-
2b showed promising efficacy in a phase 2 trial of 40 CP-CML
patients (81), and Peg-IFN alpha-2a combined with nilotinib
resulted in DMR, albeit with substantial toxic effects, in a
phase 2 study of 41 CML patients, with 7 (17%) patients
achieving MR4.5 after 1 year of treatment (82). The ongoing
TIGER trial (NCT01657604; estimated primary completion date
December 2020) aims to assess the efficacy and safety of nilotinib
compared with nilotinib plus Peg-IFN alpha-2b as first-line
therapy in newly diagnosed CP-CML patients who are Ph/BCR-
ABL positive.
An interim analysis of the PETALS study, which evaluated
cumulative rates of MR4.5 following 12 months of treatment
with nilotinib or nilotinib plus IFN in 200 newly diagnosed
CP-CML patients, showed statistically significant DMR rates in
favor of the combination treatment arm at 12 months (83).
Similarly, interim results of the PINNACLE study also suggested
that combination therapy with nilotinib plus Peg-IFN alpha-
2b results in favorable rates of molecular responses compared
with nilotinib as monotherapy (84). TFR rate data on IFN-TKI
combinations are still unknown.
Other agents are being evaluated in clinical studies, including
HQP1351 (85) and PF-114 (86), however results to date suggest
that safety may be an issue.
Other promising combinations and ongoing trials in CML
patients include ruxolitinib in combination with nilotinib (87)
or in combination with a TKI (NCT03610971), venetoclax
in combination with dasatinib (NCT02689440), pioglitazone
(a peroxisome proliferator-activated receptor γ agonist) in
combination with imatinib (88) or in combination with a
TKI (NCT02889003), dipeptidyl peptidase IV inhibitors (89),
which are also under investigation in the European clinical trial
CAMN107CNL08T (EudraCT Number: 2017-000899-28), and
the ACTIW study (NCT02767063).
A de-escalation approach to TFR is among the novel strategies
intended to improve TFR outcomes. Dose modification of TKI
therapy aims to reduce adverse events in CML patients whilst
maintaining efficacy. Indeed, a recent review concluded that dose
optimization with adequate monitoring was feasible and safe, and
improved quality of life (90).
The effect of gradual TKI withdrawal prior to discontinuation
was investigated in the non-randomized, phase 2 De-Escalation
and Stopping Treatment with Imatinib, Nilotinib, or Dasatinib
(DESTINY) study (91). At study entry, 148 patients had been
treated with imatinib, 16 with nilotinib, and 10 with dasatinib
for a median duration of 6.9 years; all patients had at least a
1-year stable MMR. Patients were assigned to the MR4 group
if all PCR measurements during the observation period were
≤0.01%, and to the MMR group if any PCR measurements
were >0.01% but ≤0.1%. TKI treatment was de-escalated to
half the standard dose for 12 months, then stopped for 24
months. Of the 125 patients in the MR4 group, 84 (67%)
achieved the primary end-point (no loss of MMR at 36 months),
with a 3-years MRFS of 72% (95% CI 64–80). Similarly, 16
of 49 (33%) patients in the MMR group completed the study,
with a 3-years MRFS of 36% (95% CI 25–53). Overall, this
study suggests that an initial TKI de-escalation period prior
to TFR in patients with stable MR4 might improve the TFR
rate, with a lower incidence of WS. The phase II, prospective
multicenter De-escAlation and discontinuation of Nilotinib
ThErapy (DANTE) trial is currently ongoing in Italy to further
elucidate this scenario.
Enhanced Detection Methods
Improved accuracy in detecting BCR-ABL1 transcripts supports
the selection of CML patients eligible for TFR, and the
emergence of digital PCR (dPCR) may offer a more sensitive
and accurate detection than real-time quantitative PCR (qPCR).
The reliability and efficiency of dPCR was evaluated in 142
CML patients treated with TKIs, assessing ≥2 years DMR using
real-time qPCR (92). dPCR detected measurable transcripts
that were undetectable by conventional real-time qPCR,
and identified differing quantities of BCR-ABL1 transcripts
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in patients within the same MR class. For the detection
and monitoring of BCR-ABL1 molecular levels, digital PCR
was more accurate and sensitive compared with real-time
qPCR, highlighting its potential to improve stable DMR
recognition and hence the selection of patients eligible for TKI
discontinuation (92).
Enhanced detection methods also include digital droplet PCR,
which was found to be predictive of TFR outcomes when tested
at the time of TKI discontinuation in CP-CML patients (93).
Notably, residual leukemic cell load determined by digital droplet
PCR was one of two key factors for predicting a successful TFR in
CP-CML patients (94).
The development of more sensitive detection methods is not
separate from the optimization of known methods. Monitoring
BCR-ABL1 using the newly implemented TaqMan system with
GUSB as reference gene (TM/GUSB) was compared with
the LightCycler quantitative reverse transcription (qRT)-PCR
system, which utilizes ABL1 as reference gene (LC/ABL1) (95).
Overall, TM/GUSB was found to be a robust and reliable method
for monitoring CML patients, showing improved sensitivity
compared with LC/ABL1. The enhanced sensitivity of TM/GUSB
may support in loss of response prediction.
Highly sensitive individualized BCR-ABL1 DNA PCR was
used to show gradually reducing levels of residual CML cells
in long-term TFR CML patients, with a continuous rate of
decline in BCR-ABL1 transcripts up to 3 years after imatinib
discontinuation demonstrated in nine patients in long-term
stable TFR (96). The likelihood of residual BCR-ABL1 in TFR
patients being due to the presence of BCR-ABL1 in clonal
lymphocytes (46), which may be reducing over time (96), needs
to be clarified.
Second Attempt at TKI Discontinuation
Whether patients who relapse on TFR should re-attempt
TKI discontinuation is currently unknown. The RE-STIM
study, which evaluated TFR in 70 CML patients who
underwent a second TKI discontinuation after a failed first
attempt, demonstrated that a first unsuccessful attempt at TKI
discontinuation did not prevent success during a second attempt
(97). In total, two thirds of patients (64%) experienced MMR
loss after a median of 5.3 months off therapy. TFR rates were 48,
42, and 35% at 12, 24, and 36 months, respectively. Univariate
analysis identified the speed of molecular relapse after the first
TKI discontinuation attempt as being the only factor significantly
associated with outcome during the second attempt; the TFR
probability at 24 months was significantly higher in patients
who remained in DMR at 3 months after the first attempt to
discontinue TKI compared with those who lost MMR within 3
months (72 vs. 36%). A more recent analysis of 106 CP-CML
patients with 41 months of follow-up from the RE-STIM study
confirmed the safety and success of a second TKI discontinuation
attempt (98). Major factors significantly associated with TFR
outcome were the speed of molecular relapse after the first TKI
discontinuation and TKI-free duration of >6 months after the
first attempt at TKI discontinuation.
Studies assessing a second TKI discontinuation attempt
after a failed first attempt and re-treatment with nilotinib
(NCT02917720), dasatinib (NCT03573596) or ponatinib
(NCT04043676) are currently ongoing.
CONCLUSIONS
The number and potency of available treatments for CML
patients have significantly increased in recent years, making
therapeutic decisions more complex and treatment goals
more ambitious. In this scenario the optimal evaluation and
management of patients’ comorbidities is needed to allow an
individualized treatment without reducing treatment options.
DMR and TFR are feasible treatment goals in CML and criteria
for TKI discontinuation in clinical practice have been published
based on expert recommendations and formal guidelines.
Optimizing treatment to reach DMR is imperative and studies
have shown that the use of second-generation TKIs, and in
particular nilotinib, may increase the proportion of potential
candidates eligible for TKI discontinuation through the reach of
faster and deeper responses, although patient selection is very
important (e.g., patients at high cardiovascular risk should be
excluded). Patient management strategies aimed at improving
TFR are essential and include communication to facilitate the
patient-physician relationship and to meet the needs of patients
(emotional and psychological). New drugs (i.e., asciminib) and
treatment strategies (i.e., IFN-α combined with a TKI and
de-escalation prior to TKI discontinuation), as well as novel
molecular monitoring strategies (i.e., digital PCR) and treatment
regimens (i.e., repeat attempts at TKI discontinuation) aimed
toward improving TFR outcomes are currently under evaluation
and may improve TFR prediction and outcomes.
Although TFR success rate is similar when stopping first- or
second-generation TKIs, second-generation TKIs lead to more
rapid and deeper molecular responses. Hence, the achievement
of TFR is becoming increasingly achievable in CML patients;
however in the near future we may further improve the path to
TFR and widen the TFR population in clinical practice.
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